Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel W Visscher

Showing results (121-130 of 122) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 122 results.
Cancer Chemotherapy and Pharmacology|April 18, 2022
A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancerJulia Manzo, Shannon Puhalla, Shalu Pahuja, et al.
Carcinogenesis|December 12, 2013
Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancerKristen S Purrington, Susan Slager, Diana Eccles, et al.
Pageof 13

Showing results (121-130 of 122) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 122 results.
Cancer Chemotherapy and Pharmacology|April 18, 2022
A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancerJulia Manzo, Shannon Puhalla, Shalu Pahuja, et al.
Carcinogenesis|December 12, 2013
Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancerKristen S Purrington, Susan Slager, Diana Eccles, et al.
Pageof 13